New York State, City sue Merck over Vioxx

Share this article:

New York State Attorney General Andrew Cuomo and New York City Mayor Michael Bloomberg have filed a joint lawsuit against Merck, alleging the drugmaker misrepresented the cardiovascular risks associated with its Vioxx painkiller.

The civil lawsuit, filed in New York State Supreme Court, seeks damages, penalties and restitution for taxpayer dollars wrongfully spent on Vioxx prescriptions. It is first case to be brought under New York State's recently enacted False Claims Act.

According to the New York Attorney General's Office, between 1999, when Vioxx was introduced, and 2004 when it was pulled from the market, Medicaid and EPIC spent over $100 million on Vioxx prescriptions in New York State. For its residents receiving Medicaid assistance, New York City paid a substantial share of those costs.

Merck said in a statement that it has not yet received the complaint filed by New York State and New York City seeking Medicaid reimbursement costs.

Merck said it intends to defend against the suit as it has defended against the Medicaid-related suits filed more than a year ago by a handful of other states including Alaska, Louisiana, Mississippi, Montana, Texas and Utah.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...